Implications of Food and Drug Administration Approval of Respiratory Syncytial Virus Prophylactic Medication

Pediatr Rev. 2023 Dec 1;44(12):723-724. doi: 10.1542/pir.2023-006246.

Authors

Ashley L Saint-Fleur¹, Catherine Kier²

Affiliations

¹ Division of Pulmonary Medicine, Boston Children's Hospital, Boston, MA.
² Division of Pulmonary Medicine, Department of Pediatrics, Stony Brook Children's Hospital, Stony Brook, NY.

PMID: 37779223
DOI: 10.1542/pir.2023-006246

No abstract available

MeSH terms

Humans
Respiratory Syncytial Virus Infections* / drug therapy
Respiratory Syncytial Virus Infections* / prevention & control
Respiratory Syncytial Virus, Human*
United States
United States Food and Drug Administration